HYDERABAD, INDIA (Nov 14, 2011) – Suven Life Sciences is presenting several data presentations from their portfolio of investigational neuroscience new chemical entities (NCEs) at SFN 2011 from 13 th to 16th of Nov held at Washington DC, USA. Neuroscience is the annual meeting of the Society for Neuroscience (SFN) and more than 30 thousand Neuro- Scientists from all over the world covering all the major Pharma, biotech and research institutes will be participating Suven’s nine (9) data presentations covers the early-stage compounds from Histamine-3 receptor antagonist, Nicotinic acetylcholine alpha-4-beta-2 receptor agonist and antagonist, Serotonin 5-HT4 receptor agonist in addition to 5HT6 antagonists to treat unmet medical needs of patients living with cognitive dysfunction associated with Alzheimer’s, Schizophrenia, ADHD; Depression & Mood Disorders and Neuropathic Pain. These data presentation highlights Suven’s continued commitment to exploring new treatment options addressing unmet medical need through novel mechanisms and targets and address a market size of more than $30 billion.
During SFN-2011 Suven lined up several face to face meetings with major Pharma and Biotech companies to explore integrated collaborative research programs (CRP) and also Drug Discovery and Development Support Services (DDDSS) in addition to continued discussions with global pharma majors regarding their clinical candidate SUVN-502.
Suven is committed to neuroscience research and for development of new treatments for neurological disorders. Suven’s discovery research focuses on Central Nervous System (CNS) disorders through novel mechanisms using small-molecule medicinal chemistry approaches. Suven’s CNS drug discovery scientists at Hyderabad, India are pursuing innovative ways to develop treatments for a variety of CNS disorders like Alzheimer’s, Schizophrenia, Depression, Cognitive disorders, Sleep, Neurodegeneration and Obesity through CNS targets.
For more information on Suven, please visit our Web site at http://www.suven.com
